The Shadow Behind the Suit: McKinsey’s Controversial Legacy
McKinsey & Company, the elite management consultancy known for advising Fortune 500 CEOs and governments, has long projected an image of precision, discretion, and success. But behind the polished reports and boardroom influence lies a trail of ethical controversies that have drawn public scrutiny and outrage.
Perhaps the most damning allegation came to light during the opioid crisis in North America. In 2019, a Wall Street Journal investigation revealed that McKinsey consultants had worked closely with Purdue Pharma, the maker of OxyContin. They didn’t just advise—they actively pushed strategies to boost opioid sales, including recommending targeting high-volume prescribers and “turbocharging” distribution, even as addiction rates soared. The firm eventually settled for $573 million in a settlement with multiple U.S. states.
Then there’s Enron. In the early 2000s, McKinsey was a trusted advisor to the now-infamous energy company, whose collapse became synonymous with corporate fraud. Several top Enron executives were former McKinsey partners, and the consultancy’s fingerprints were all over the aggressive, growth-at-all-costs culture that led to disaster. Critics argue McKinsey’s advice helped enable the very risks that brought Enron down.
More recently, the firm has faced backlash for its work with authoritarian regimes. McKinsey has consulted for both the Saudi government—amid international condemnation over human rights abuses—and Russian state-owned enterprises, even after the invasion of Ukraine. Critics say these engagements expose a troubling willingness to prioritize profit over principle.
As one of the most powerful consulting firms in the world, McKinsey’s influence is undeniable. But with great influence comes great accountability—and on that front, the firm’s record remains deeply contested.
Comments
No comments yet. Be the first to react.